Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes.
Carol J LevyGrenye O'MalleyDan RaghinaruYogish C KudvaLori M B LaffelJordan E PinskerJohn W LumSue A Brownnull nullPublished in: Diabetes technology & therapeutics (2022)
Objective: To analyze insulin delivery and glycemic metrics throughout the menstrual cycle for women with type 1 diabetes using closed loop control (CLC) insulin delivery. Methods: Menstruating women using a CLC system in a clinical trial were invited to record their menstrual cycles through a cycle-tracking application. Sixteen participants provided data for this secondary analysis over three or more complete cycles. Insulin delivery and continuous glucose monitoring (CGM) data were analyzed in relation to reported cycle phases. Results: Insulin delivery and CGM metrics remained consistent during cycle phases. Intraparticipant variability of CGM metrics and weight-based insulin delivery did not change through cycle phases. Conclusions: For this sample of menstruating women with type 1 diabetes using a CLC system, insulin delivery and glycemic metrics remained stable throughout menstrual cycle phases. Additional studies in this population are needed, particularly among women who report variable glycemic control during their cycles. Trial Registration: NCT03591354.
Keyphrases
- glycemic control
- type diabetes
- polycystic ovary syndrome
- blood glucose
- clinical trial
- insulin resistance
- weight loss
- pregnancy outcomes
- cervical cancer screening
- body mass index
- randomized controlled trial
- electronic health record
- study protocol
- pregnant women
- blood pressure
- skeletal muscle
- phase iii
- machine learning
- artificial intelligence
- double blind
- placebo controlled